ABSTRACT
Background: The objective of present study was to assess the drug utilization pattern among the geriatric patients. Methods: Totally, 150 prescriptions of patients’ ≥65 years admitted in the medicine inpatient department of MVJ Medical College and Research Hospital, Hoskote were noted from September 2013 to March 2014 and demographic profile, drug utilization pattern, commonly used drugs as per anatomical therapeutic chemical classification (ATC) and WHO core indicators were assessed after taking informed consent from the patients. Results: Out of 150 patients, average age of geriatric patients was 66.83 years with female preponderance (59%). Maximum number of patients were having respiratory disorders (66.67%) followed by diabetes mellitus (35.3%), and cardiovascular diseases (32.67%). 76% patients had co-morbid diseases like diabetes mellitus (n=53), hypertension (n=49), and chronic obstructive pulmonary disease (n=41). A total of 849 drug formulations, containing 1050 active ingredients, were prescribed with average number of 7 (1050/150) drugs per prescription. Only 70 formulations were prescribed by their generic names, which is less than that prescribed by their brand names 779 and total of 146 (17.19%) drugs were prescribed as fixed dose combinations. Only 45.47% drugs were according to WHO Essential Medicines List. Drugs acting on respiratory system (n=189) were the most commonly used drugs in our study followed by drugs acting on the gastrointestinal system (n=130), antimicrobials (n=113), cardiovascular system (n=112), endocrine (n=83), and nutritional supplements (n=72). Polypharmacy was prevalent in 62% and about 22.67% of patients received <5 drugs. Pantoprazole was most frequently prescribed drug followed by aspirin 75 mg, adrenergic, and anticholinergic bronchodilators. Conclusion: Thus, irrational prescribing and polypharmacy were prevalent among elderly. Drug utilization data can help in assessing the quality of care given to the geriatric patients and promote rational use of medicines.
ABSTRACT
Background: The magnitude of improvement seen with present conventional medicines for anxiety and depression remain disappointing thereby providing a scope for the study of newer drugs. In the literature, there is evidence demonstrating the modulation of N-methyl-D-aspartate (NMDA)receptors in anxiety and depression. The present study is undertaken to evaluate the antianxiety effect of memantine in elevated plus maze (EPZ) test and its antidepressant effect in tail suspension test (TST)in Swiss albino mice. Methods: Animals were divided into six groups (n=6). First group mice were given normal saline (10 ml/kg), second group were administered lorazepam (0.5 mg/kg), third group with memantine (3 mg/kg) and fourth group with memantine plus lorazepam, fi fth group was administered amitriptyline (10 mg/kg)and sixth group received memantine plus amitriptyline. All drugs were administered by intraperitoneal route daily for 7 consecutive days. Results were analyzed by one-way ANOVA followed by post-hoc Tukey’s test. Results: Memantine treated mice showed signifi cant increase (p<0.001)in time spent and number of entries in open arm and signifi cant decrease in time spent and number of entries in closed arm in EPZ when compared to control group. Duration of immobility was signifi cantly (p<0.001)reduced in animals treated with memantine when compared to the control group in TST. Conclusions: NMDA antagonist, memantine has showed signifi cant antianxiety effect in EPZ test and antidepressant effect in TST.
ABSTRACT
Azithromycin was given to 55 cases of lower respiratory tract infections in the doses of 500 mg on day 1, followed by 250 mg on days 2-5. It produced bacteriological cure in 70.8% patients and clinical cure or improvement in 69.09% of patients. 4.27% of patients had throat colonisation with new organisms, of which 9.09% needed a second antibiotic. The drug was well tolerated and minor side effects were noted. Gastrointestinal disturbances (16.36%) headache and giddiness (14.55%), rash (3.64%) were the noted side effects. Reduction of platelet count by 50% occurred in 12.29% of the cases compared to 0.2% reported earlier. But this thrombocytopenia was clinically not significant, as it did not cause any symptoms.